Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

The effectiveness of the tyrosine kinase inhibitor ALK (TKI) for non-small cell lung cancer has been confirmed. However, resistance to ALK-TKIs seems inevitable. Mutations in the ALK kinase domain have been reported as an important mechanism of acquired resistance to ALK therapy. However, patients w...

Full description

Bibliographic Details
Main Authors: Jiuzhou Zhao, Xiang Li, Ruizhe Fan, Yaping Qin, Zhizhong Wang, Bo Wang, Shaomei Li, Jianfeng Fan, Xinxin Wu, Hongxia Liu, Yuping Guan, Yinfeng Liang, Xiao Zhang, Yongjun Guo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
non-small cell lung cancer (NSCLC)
next generation sequencing (NGS)
EML4-ALK
F1174L
S1189C
de novo mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1060460/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1060460/full

Similar Items